Galapagos NV (NASDAQ:GLPG) Given Consensus Recommendation of “Reduce” by Analysts

Galapagos NV (NASDAQ:GLPG) has earned a consensus rating of “Reduce” from the seven analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $30.75.

Several analysts have recently weighed in on GLPG shares. Kepler Capital Markets lowered Galapagos from a “hold” rating to a “reduce” rating in a report on Wednesday, November 20th. Royal Bank of Canada lowered their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Friday, November 1st. Leerink Partners assumed coverage on shares of Galapagos in a report on Monday, September 9th. They issued a “market perform” rating and a $24.00 target price on the stock. Finally, Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a report on Monday, September 9th.

Galapagos Stock Performance

GLPG opened at $27.21 on Thursday. The business has a 50 day moving average price of $27.63 and a two-hundred day moving average price of $27.36. Galapagos has a 1-year low of $24.16 and a 1-year high of $42.46.

Hedge Funds Weigh In On Galapagos

Several institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC increased its holdings in shares of Galapagos by 56.7% during the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 446 shares during the last quarter. GAMMA Investing LLC boosted its position in Galapagos by 140.7% during the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 736 shares during the period. Signaturefd LLC grew its holdings in Galapagos by 48.1% during the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,258 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Galapagos by 63.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,510 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after buying an additional 814 shares during the last quarter. 32.46% of the stock is currently owned by institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.